Modular Medical discloses material weakness in internal controls
Modular Medical added a new risk factor to its 2026 10-K disclosing a material weakness in internal control over financial reporting. The company, an early-stage medical device maker that reported net losses of $28.2 million for the year ended March 31, 2026, also expanded disclosure of its dependence on future capital raises, noting it has no current revenues and expects to continue incurring losses for the foreseeable future as it commercializes its Pivot insulin pump, which commenced commercial availability and initial shipments in June 2026.
Key facts
- Material weakness in internal control over financial reporting newly disclosed in 2026 10-K
- Net losses of approximately $28.2 million for the year ended March 31, 2026
- Net losses of approximately $18.8 million for the year ended March 31, 2025
- Pivot insulin pump announced commercially available in June 2026 with initial shipments commenced
- Federal net operating loss carryforwards of $74.6 million as of March 31, 2026
- State net operating loss carryforwards of $93.6 million as of March 31, 2026
- Federal R&D tax credit carryforwards of $3.2 million expiring between 2038 and 2045
- No current revenues to cover operating expenses
- Early commercial-stage company with limited operating history
Why it matters
The material weakness admission signals control gaps that could affect the reliability of the company's financial reporting at a critical stage—just as it is beginning commercial operations and will require substantial capital raises to fund ongoing losses and expansion.
Share
Derived from 10-K filed 2026-06-29. Not investment advice. View the source filing on SEC.gov →